| James Walker, EDD | |
|
671 Hoes Ln, Piscataway, NJ 08854-5627 | |
| (800) 969-5300 | |
| Not Available |
| Full Name | James Walker |
|---|---|
| Gender | Male |
| Speciality | Rehabilitation Counselor |
| Location | 671 Hoes Ln, Piscataway, New Jersey |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033297312 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103T00000X | Psychologist | TP-023-291 (New Jersey) | Primary |
| 225C00000X | Rehabilitation Counselor | (New Jersey) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| James Walker, EDD 671 Hoes Ln, P. O. Box 1392, Piscataway, NJ 08854-5627 Ph: (732) 235-5940 | James Walker, EDD 671 Hoes Ln, Piscataway, NJ 08854-5627 Ph: (800) 969-5300 |
News Archive
The immunotherapy drug pembrolizumab has demonstrated a favorable safety profile and "promising durable clinical activity" in pretreated patients who exhibit high levels of the PD-L1 protein in advanced stages of small cell lung cancer (SCLC) – an aggressive form of the disease
Social isolation and loneliness have affected many people during the Covid-19 pandemic, especially those with limited access to digital technology.
AxoGen, Inc. today reported third quarter of 2011 revenues of $1.1 million, a 42.5% increase over $0.8 million reported during the third quarter of 2010.
Scientists from the University of Sydney on Saturday have announced that they have developed a vaccine to help halt the progression of Alzheimer's disease of humans. The progress of neurodegenerative condition affects more than 35 million people worldwide.
› Verified 2 days ago